Immunosuppressors and immunomodulators in Neurology - Part I: a guide for management of patients underimmunotherapy
Authors:
- Fabiano Ferreira AbrantesFAFabiano Ferreira Abrantes
- Marianna Pinheiro Moraes de MoraesMMMarianna Pinheiro Moraes de Moraes
- José Marcos Vieira de Albuquerque FilhoJFJosé Marcos Vieira de Albuquerque Filho
- Jéssica Monique Dias AlencarJAJéssica Monique Dias Alencar
- Alexandre Bussinger LopesALAlexandre Bussinger Lopes
- Wladimir Bocca Vieira de Rezende PintoWladimir Bocca Vieira de Rezende Pinto
- Paulo Victor Sgobbi de SouzaPaulo Victor Sgobbi de Souza
- Enedina Maria Lobato de OliveiraEOEnedina Maria Lobato de Oliveira
- Acary de Souza Bulle de OliveiraAcary de Souza Bulle de Oliveira
- José Luiz PedrosoJPJosé Luiz Pedroso
- Orlando Graziani Povoas BarsottiniOBOrlando Graziani Povoas Barsottini
Open Access
- 1 November 2021
- journal article
- review article
- Published by FapUNIFESP (SciELO) in Arquivos de Neuro-Psiquiatria
- Vol. 79 (11) , 1012-1025
Abstract
For patients with autoimmune diseases, the risks and benefits of immunosuppressive or immunomodulatory treatment are a matter of continual concern. Knowledge of the follow-up routine for each drug is crucial, in order to attain better outcomes and avoid new disease activity or occurrence of adverse effects. To achieve control of autoimmune diseases, immunosuppressive and immunomodulatory drugs act on different pathways of the immune response. Knowledge of the mechanisms of action of these drugs and their recommended doses, adverse reactions and risks of infection and malignancy is essential for safe treatment. Each drug has a specific safety profile, and management should be adapted for different circumstances during the treatment. Primary prophylaxis for opportunistic infections and vaccination are indispensable steps during the treatment plan, given that these prevent potential severe infectious complications. General neurologists frequently prescribe immunosuppressive and immunomodulatory drugs, and awareness of the characteristics of each drug is crucial for treatment success. Implementation of a routine before, during and after use of these drugs avoids treatment-related complications and enables superior disease control.Keywords
This publication has 78 references indexed in Scilit:
- Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosisNature Reviews Drug Discovery, 2010
- A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple SclerosisNew England Journal of Medicine, 2010
- Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetateMultiple Sclerosis Journal, 2010
- Cyclophosphamide and cancer: golden anniversaryNature Reviews Clinical Oncology, 2009
- Chronic hepatitis B: Update 2009 #Hepatology, 2009
- Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-? antagonistsBritish Journal of Dermatology, 2007
- Mycophenolate mofetil and neurological diseasesLupus, 2005
- Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseasesNeurological Sciences, 2003
- Systemic corticosteroid therapy---side effects and their managementBritish Journal of Ophthalmology, 1998
- Double-Blind Trial of Dexamethasone versus Methylprednisolone in Multiple Sclerosis Acute RelapsesEuropean Neurology, 1994